In order to search biomarkers for pancreatic cancer that can facilitate to monitor treatment efficacy or early detection, Porterfield et al. (22) performed an in-depth LC-MS/MS analysis of the proteome in pancreatic ductal fluid from normal and pancreatic adenocarcinoma patients, and Reg3A was found increased in cancer ductal fluid compared to normal. This evidence concerns the gene REG3A and familial pancreatic carcinoma.